Novolytics Ltd., Barclays Venture Centre, Coventry, UK.
Drug Discov Today. 2009 Jun;14(11-12):536-40. doi: 10.1016/j.drudis.2009.03.006. Epub 2009 Mar 11.
There is a renaissance of interest in the antimicrobial potential of phages as more pathogens become multiply antibiotic resistant. Phage therapy is not a new concept, and it is important to ask why it is not part of the current repertoire of western medicine despite the fact that it has been continuously and extensively used in Eastern Europe for almost a century. Answering this question successfully will, largely, determine whether phage therapy can gain the credibility needed to overcome the scientific, financial and regulatory hurdles facing its adoption in mainstream clinical practice. Despite a paucity of such information from human studies, pharmacokinetic data and clinical outcomes from animal studies are currently providing convincing evidence for the safety and efficacy of phage therapy.
随着越来越多的病原体对多种抗生素产生耐药性，人们对噬菌体的抗菌潜力重新产生了兴趣。噬菌体疗法并不是一个新概念，重要的是要问，尽管噬菌体在东欧已经连续广泛使用了将近一个世纪，但为什么它不是当今西方医学的一部分。成功回答这个问题在很大程度上将决定噬菌体疗法是否能够获得克服其在主流临床实践中采用所面临的科学、财务和监管障碍所需的可信度。尽管人类研究中缺乏此类信息，但来自动物研究的药代动力学数据和临床结果目前正在为噬菌体疗法的安全性和有效性提供令人信服的证据。
